药物发现和开发的基本原则 1336条(本栏目收费,不能显示细节,电话13136136841)
“3 + 3” study, 397–398 398
chronic disease/conditions, 399 399
positive signal identification, 399–400 400
randomized phase II trial, 401, 401f 401
single arm phase II study, 400–401,400f 400
staged trial design, 401, 401f 401
trial design and outcome measure, 400 400
crossover trial design, 405–406, 405f 405
financial risk, 402–403 403
non-life-threatening conditions, 407 407
objective endpoints, 405 405
patient management vs. candidate 0
placebo control group, 404 404
subjective endpoints, 405 405
treatment regimen, 405–406, 405f 405
phase IV, 10–11, 407–408 408
pharmacoeconomic studies, 408 408
safety and efficacy, 407–408 408
Coenzyme A, 99–101, 102f 102
Coenzyme Q, 99–101, 102f 102
Comet assay, 359, 359f 359
Competitive inhibitors, 101–103, 103f 103
Computational chemistry, 50–53, 51f–52f 52
Congestive heart failure (CHF), 329–332, 330f 330